BACKGROUND: During the time of lowest white blood cell count (nadir) of allogeneic hematopoietic stem cell transplantation (allo-HSCT), cancer patients suffer from tremendous symptom burden related to therapy that requires intensive patient care. However, the mechanism underlying the development of multiple symptoms has not been established. METHODS: To explore the role of inflammatory cytokines in the development of treatment-related symptoms, we studied dynamic changes in symptoms and in serum concentrations of inflammatory cytokines (interleukin [IL]-6, IL-8, soluble tumor necrosis factor receptor 1 [sTNF-R1], IL-1 receptor antagonist, and IL-12p40p70) from pretherapy throughout the first 30 days of allo-HSCT in 30 patients with acute myelogenous leukemia or myelodysplastic syndrome. We measured multiple symptoms repeatedly using the M. D. Anderson Symptom Inventory. Mixed-effects modeling was used to analyze longitudinal data. RESULTS: In response to conditioning and stem-cell infusion, serum levels of IL-6 and the severity of multiple symptoms increased rapidly and peaked at nadir. From baseline to nadir (approximately Day 8 post-transplantation), increase in IL-6 was significantly associated with worsening of the most severe symptoms (fatigue, poor appetite, pain, drowsiness, dry mouth, and disturbed sleep; P< .01). During the first 30 days after transplantation, increases in IL-6 (P< .001) and sTNF-R1 (P< .05) significantly predicted the increasing severity of these symptoms. CONCLUSIONS: These results suggest that release of systemic inflammatory cytokines, mainly IL-6, corresponds to an increase in treatment-related multiple-symptom burden during the nadir period of allo-HSCT. (c) 2008 American Cancer Society.
BACKGROUND: During the time of lowest white blood cell count (nadir) of allogeneic hematopoietic stem cell transplantation (allo-HSCT), cancerpatients suffer from tremendous symptom burden related to therapy that requires intensive patient care. However, the mechanism underlying the development of multiple symptoms has not been established. METHODS: To explore the role of inflammatory cytokines in the development of treatment-related symptoms, we studied dynamic changes in symptoms and in serum concentrations of inflammatory cytokines (interleukin [IL]-6, IL-8, soluble tumor necrosis factor receptor 1 [sTNF-R1], IL-1 receptor antagonist, and IL-12p40p70) from pretherapy throughout the first 30 days of allo-HSCT in 30 patients with acute myelogenous leukemia or myelodysplastic syndrome. We measured multiple symptoms repeatedly using the M. D. Anderson Symptom Inventory. Mixed-effects modeling was used to analyze longitudinal data. RESULTS: In response to conditioning and stem-cell infusion, serum levels of IL-6 and the severity of multiple symptoms increased rapidly and peaked at nadir. From baseline to nadir (approximately Day 8 post-transplantation), increase in IL-6 was significantly associated with worsening of the most severe symptoms (fatigue, poor appetite, pain, drowsiness, dry mouth, and disturbed sleep; P< .01). During the first 30 days after transplantation, increases in IL-6 (P< .001) and sTNF-R1 (P< .05) significantly predicted the increasing severity of these symptoms. CONCLUSIONS: These results suggest that release of systemic inflammatory cytokines, mainly IL-6, corresponds to an increase in treatment-related multiple-symptom burden during the nadir period of allo-HSCT. (c) 2008 American Cancer Society.
Authors: James M Reuben; Bang-Ning Lee; Changping Li; Jesus Gomez-Navarro; Viviana A Bozon; Charla A Parker; Ingrid M Hernandez; Carolina Gutierrez; Gabriel Lopez-Berestein; Luis H Camacho Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Andrew H Miller; Sonia Ancoli-Israel; Julienne E Bower; Lucile Capuron; Michael R Irwin Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Li Mao; Charles S Cleeland; Ritsuko R Komaki; Gary M Mobley; Zhongxing Liao Journal: Brain Behav Immun Date: 2010-03-29 Impact factor: 7.217
Authors: Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: William A Wood; Allison M Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; Bryce B Reeve Journal: Biol Blood Marrow Transplant Date: 2012-12-16 Impact factor: 5.742
Authors: Jennifer M Knight; J Douglas Rizzo; Brent R Logan; Tao Wang; Jesusa M G Arevalo; Jeffrey Ma; Steve W Cole Journal: Clin Cancer Res Date: 2015-08-18 Impact factor: 12.531
Authors: Nina Shah; Qiuling Shi; Loretta A Williams; Tito R Mendoza; Xin Shelley Wang; James M Reuben; Patrick M Dougherty; Qaiser Bashir; Muzaffar H Qazilbash; Richard E Champlin; Charles S Cleeland; Sergio A Giralt Journal: Biol Blood Marrow Transplant Date: 2015-08-05 Impact factor: 5.742
Authors: Xin Shelley Wang; Qiuling Shi; Nina D Shah; Cobi J Heijnen; Evan N Cohen; James M Reuben; Robert Z Orlowski; Muzaffar H Qazilbash; Valen E Johnson; Loretta A Williams; Tito R Mendoza; Charles S Cleeland Journal: Clin Cancer Res Date: 2014-01-14 Impact factor: 12.531